14-day Premium Trial Subscription Try For FreeTry Free
NYSE:RNN
Delisted

Rexahn Pharmaceuticals, Inc. Stock Signals

$5.24
+0 (+0%)
At Close: Sep 19, 2019

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 41 days ( 0 % )
Last Price $5.24 0 %
High/ Low $5.24 - $5.24 0%
Chg 7 Days N/A $5.24 $5.24
Chg 30 Days N/A $5.24 $5.24
Chg 12 mos 186.34 % $1.83 $5.24
Trend - 3 mos N/A Width: 0 %
Trend - 12 mos 176.48 % Width: 200.46 %
Pred. range - 3 mos N/A - N/A -100.00 % - -100.00 %
Pred. range - 12 mos $8.56 - $25.73 63.42 % - 391.02 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Jul 25, 2019 - 40 days
Short/Long MA avg 3 mos Sell Jul 25, 2019 - 40 days
Short MA avg 12 mos Sell Jun 21, 2019 - 63 days
Long MA avg 12 mos Sell Aug 29, 2019 - 15 days
Short/Long MA avg 12 mos Sell Aug 29, 2019 - 15 days
Pivot Short Buy Sep 18, 2019 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company’s clinical stage oncology candidates include Archexin that completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; RX-3117, which is in Phase Ib clinical trial for the treatment of patients with solid tumors; and Supinoxin that is in Phase I clinical trial for patients wit... RNN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT